Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, Hackensack University Medical Center, shared on LinkedIn:
“AstraZeneca has licensed a novel EGFR inhibitor aimed at addressing resistance in certain lung cancers. The clinical data was ahead of the approval.
Oncologists and patients in the US were ready to use Sunvozertinib but the regulatory agreements were not. Collective effort is needed to reduce time between innovation and patients.”